Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial

被引：0
|
作者：
Ergun, Yakup [1 ]
机构：
[1] Antalya City Hosp, Dept Med Oncol, TR-07080 Antalya, Turkiye
来源：
LANCET | 2024年 / 404卷 / 10450期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [31] Sacituzumab govitecan in triple-negative breast cancer
    de Nonneville, Alexandre
    Goncalves, Anthony
    Mamessier, Emilie
    Bertucci, Francois
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [32] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [33] Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Tolaney, Sara M.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva M.
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Valdez, Theresa
    Yoon, Oh Kyu
    Wang, Hao
    Verret, Wendy
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [35] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in HR+/HER2-metastatic breast cancer (MBC)
    Tolaney, Sara
    Schmid, Peter
    Bardia, Aditya
    Marme, Frederik
    Loirat, Delphine
    Sharma, Priyanka
    Wang, Hao
    Fu, Olivia
    Verret, Wendy
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
    Connie Kang
    Targeted Oncology, 2024, 19 : 289 - 296
  • [38] Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Tesch, H.
    Tolaney, S.
    Bardia, A.
    Marme, F.
    Cortes, J.
    Schmid, P.
    Loirat, D.
    Tredan, O.
    Ciruelos, E.
    Dalenc, F.
    Pardo, Gomez P.
    Jhaveri, K.
    Delaney, R.
    Valdez, T.
    Yoon, O. K.
    Wang, H.
    Verret, W.
    Rugo, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 29 - 30
  • [39] Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
    Rizzo, A.
    Rinaldi, L.
    Massafra, R.
    Cusmai, A.
    Guven, D. C.
    La Forgia, D.
    Latorre, A.
    Giotta, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S356 - S356
  • [40] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
12345